Alembic Pharmaceuticals has announced that a meeting of its Board of Directors will be held on May 15, 2026. The primary objective of this session is to review and approve the company’s audited financial results for the quarter and financial year ending March 31, 2026. Additionally, the Board will consider the recommendation of a dividend on equity shares for the concluded financial year.
Upcoming Board Meeting Details
The management of Alembic Pharmaceuticals has confirmed that the Board of Directors will convene on Friday, May 15, 2026. This meeting is critical as the company prepares to finalize its performance metrics for both the final quarter and the full financial year concluded on March 31, 2026.
Financial and Dividend Review
During the scheduled meeting, the Board will focus on two major agenda items. First, they will consider and approve the audited financial statements for the period ending March 31, 2026. Second, the leadership team will deliberate on the declaration of a dividend for equity shareholders for the same financial year, subject to their internal review and recommendation.
Trading Window Update
In adherence to internal compliance protocols, the trading window for dealing in company securities has been closed since April 1, 2026. This window is set to reopen 48 hours following the official declaration of the company’s financial results to the public.
Source: BSE
